22
Participants
Start Date
June 5, 2017
Primary Completion Date
March 13, 2018
Study Completion Date
March 13, 2018
Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)
"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
DERMING, Milan
Lead Sponsor
Derming SRL
OTHER